Join our CEO Harald Schnidar's talk "AI powered Digital Dermatology in Skin Drug Research" at the Xista Talk hosted by the Austrian Institute of Science and Technology (ISTA).

The study uses photobiomodulation at different wavelengths for wound care in diabetic wounds and resulted in signficant positive effects objectively shown by the medical device software Scarletred®Vision.

Topical Bimiralisib, used in patients with the rare cutaneous form of T-cell lymphoma, known as Mycosis fungoides, and healthy patients, showed substantial results regarding cutaneous drug levels.

SCARLETRED visits the hybrid EADV congress in Milan from September 7-9, 2022, to present the results of a new rosacea study that used Scarletred®Vision to measure the effectiveness of a new treatment.

Post-Marketing Studies play an integral role in gathering information about safety and efficacy on a large scale. However, monitoring adverse events and patient-reported outcomes in a real-world setting can be challenging.

Following a successful launch in Europe in 2019, and a tremendous online experience in 2021, the 3rd Dermatology Drug Development Europe Summit, returns in April 2022 in Frankfurt, Germany.

Chronic spontaneous urticaria poses challenges such as long term treatment options. Innovations like Scarletred®Vision aid monitoring and research, offering real-time data and tissue classification for personalized treatment.

Starting in May 2022, the monkeypox outbreak has raised public health concerns. The small pox vaccine shows to be effective, but availability is limited. Moreover, the clinical image of a rash varies on different skin tones.

Digitalization and telemedicine have shown significant advancements in the medical industry. Still, clinical research will continue to need high-quality tools to conduct trials efficiently and decrease strain on patients.